We are not a typical fund team. There are no suits and slide decks—only the people necessary to unlock the opportunity.
Gianpaolo Grazioli — Founder, Scientific Interface
When a close family member was diagnosed with Alzheimer’s, Gianpaolo Grazioli, like many others, was deeply affected. What began as a personal tragedy became the catalyst for a sixteen-year journey into neurobiology at the molecular level. Determined to uncover the overlooked drivers of disease, he worked from first principles to build an evidence-based theory of neurodegeneration that connects breakthrough science to market reality.
At Neurohedge Capital, Gianpaolo now serves as the bridge between senior research collaborators and investors, transforming complex biology into asymmetric opportunities that are confidential, actionable, and defensible. Each thesis is grounded in original research and proprietary biology, creating an edge that cannot be replicated without direct access to the underlying science.
His approach reflects both rigor and conviction through close collaboration with scientists and physicians, patent-level experimentation, and disciplined strategies designed to generate falsifiable predictions and measurable public signals. By aligning scientific discovery with capital discipline, Neurohedge Capital converts insight into execution, delivering strategies ahead of their time, where opportunities remain untapped.
Scientific Advisors — Confidential
We work with a network of practicing neurologists, molecular biologists, pharmacologists, and translational researchers. Most hold senior roles at academic institutions or R&D divisions and prefer to remain anonymous due to conflict-of-interest restrictions.
Their work informs the edge. They are not visible, but they are embedded.
